Shattuck Labs Extends Cash Runway to 2029, Advances SL-325 to Phase 2, and Raises $26.8M
Summary
Shattuck Labs reported a widened Q1 net loss but significantly extended its cash runway into 2029 through successful ATM sales and warrant exercises, while also advancing its lead clinical candidate, SL-325, to Phase 2.
Key Events
-
Q1 2026 Financial Results
Shattuck Labs reported a net loss of $14.8 million for Q1 2026, widening from $13.7 million in Q1 2025. Net loss per share improved to $(0.13) from $(0.27) due to a higher weighted-average share count.
-
Cash Runway Extended to 2029
Management believes current cash and cash equivalents of $90.4 million are sufficient for at least the next 12 months. Critically, assuming full exercise of outstanding common stock warrants, the company projects its cash runway will extend into 2029.
-
Successful Capital Raises
The company raised $21.4 million by selling 5,000,000 shares through its At-The-Market (ATM) facility at an average price of $4.28 per share. Additionally, $5.4 million was generated from the exercise of common stock warrants.
-
Clinical Pipeline Progress
The Phase 1 clinical trial for lead product candidate SL-325 is expected to complete in Q2 2026, with a Phase 2 clinical trial in Crohn's Disease planned for initiation in Q3 2026.
Analysis
Shattuck Labs' Q1 2026 report, while showing a widened net loss, delivers critical positive updates for a clinical-stage biotechnology company. The most significant development is the projected extension of its cash runway into 2029, contingent on the full exercise of outstanding common stock warrants. This substantially de-risks the company's near-term funding requirements. The company successfully raised $21.4 million through its At-The-Market (ATM) facility at an average price of $4.28 per share, which, while dilutive and below the current market price, provides essential capital. An additional $5.4 million was generated from common stock warrant exercises. Furthermore, the company announced plans to complete the Phase 1 clinical trial for its lead candidate, SL-325, in Q2 2026 and initiate a Phase 2 trial in Crohn's Disease in Q3 2026, marking important progress in its pipeline development. These combined factors indicate improved financial stability and clinical momentum.
At the time of this filing, STTK was trading at $6.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $504.9M. The 52-week trading range was $0.71 to $8.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.